Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $4,793 | 2 | 50.6% |
| Food and Beverage | $4,640 | 177 | 49.0% |
| Travel and Lodging | $44.23 | 1 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $5,569 | 38 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $637.36 | 14 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $633.99 | 31 | $0 (2023) |
| GlaxoSmithKline, LLC. | $476.31 | 10 | $0 (2020) |
| PFIZER INC. | $219.82 | 12 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $207.21 | 6 | $0 (2022) |
| Lilly USA, LLC | $205.75 | 10 | $0 (2022) |
| Gilead Sciences, Inc. | $181.84 | 5 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $175.00 | 3 | $0 (2023) |
| Axsome Therapeutics, Inc. | $118.75 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $231.93 | 3 | Axsome Therapeutics, Inc. ($118.75) |
| 2023 | $425.74 | 10 | AstraZeneca Pharmaceuticals LP ($269.82) |
| 2022 | $495.49 | 19 | Novo Nordisk Inc ($189.60) |
| 2021 | $650.47 | 32 | Takeda Pharmaceuticals U.S.A., Inc. ($263.23) |
| 2020 | $608.04 | 30 | Takeda Pharmaceuticals U.S.A., Inc. ($117.10) |
| 2019 | $5,648 | 26 | Novo Nordisk Inc ($4,849) |
| 2018 | $964.00 | 42 | GlaxoSmithKline, LLC. ($273.11) |
| 2017 | $452.92 | 18 | Novo Nordisk Inc ($161.15) |
All Payment Transactions
180 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/25/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $118.75 | General |
| Category: Psychology/Psychiatric | ||||||
| 05/15/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $91.93 | General |
| Category: PSYCHIATRY | ||||||
| 05/14/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: BIOLOGIC | ||||||
| 08/08/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: Respiratory | ||||||
| 07/12/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $34.05 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/07/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $124.10 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/30/2023 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/25/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: INSOMNIA | ||||||
| 05/03/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: INSOMNIA | ||||||
| 04/04/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: INSOMNIA | ||||||
| 03/03/2023 | Novo Nordisk Inc | Saxenda (Drug), Wegovy | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: Obesity | ||||||
| 03/03/2023 | Novo Nordisk Inc | Saxenda (Drug), Wegovy | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Obesity | ||||||
| 03/01/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Respiratory | ||||||
| 12/22/2022 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: INSOMNIA | ||||||
| 10/12/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: Diabetes | ||||||
| 10/06/2022 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $31.01 | General |
| Category: IMMUNOLOGY | ||||||
| 09/22/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: Diabetes | ||||||
| 09/13/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/09/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $8.84 | General |
| Category: Diabetes | ||||||
| 07/19/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: Diabetes | ||||||
| 06/16/2022 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug) | Food and Beverage | In-kind items and services | $29.32 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 06/15/2022 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $30.65 | General |
| Category: IMMUNOLOGY | ||||||
| 06/14/2022 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: Diabetes | ||||||
| 05/24/2022 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $125.08 | General |
| Category: Diabetes | ||||||
| 05/20/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.09 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 60 | 363 | $35,629 | $16,872 |
| 2022 | 1 | 15 | 49 | $11,044 | $4,736 |
| 2021 | 2 | 55 | 98 | $18,685 | $8,122 |
| 2020 | 1 | 35 | 121 | $22,975 | $6,781 |
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 12 | 153 | $10,809 | $5,384 | 49.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 13 | 42 | $9,466 | $4,101 | 43.3% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 12 | 76 | $8,901 | $3,628 | 40.8% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 12 | 81 | $6,061 | $3,556 | 58.7% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2023 | 11 | 11 | $391.71 | $202.29 | 51.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 49 | $11,044 | $4,736 | 42.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 41 | 77 | $13,496 | $5,760 | 42.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 14 | 21 | $5,189 | $2,362 | 45.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 35 | 121 | $22,975 | $6,781 | 29.5% |
About Dr. Harminder Kaur, MD
Dr. Harminder Kaur, MD is a Internal Medicine healthcare provider based in Frederick, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083702799.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Harminder Kaur, MD has received a total of $9,477 in payments from pharmaceutical and medical device companies, with $231.93 received in 2024. These payments were reported across 180 transactions from 34 companies. The most common payment nature is "Consulting Fee" ($4,793).
As a Medicare-enrolled provider, Kaur has provided services to 165 Medicare beneficiaries, totaling 631 services with total Medicare billing of $36,512. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Frederick, MD
- Active Since 10/10/2006
- Last Updated 01/13/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1083702799
Products in Payments
- Saxenda (Drug) $5,090
- CUVITRU (Biological) $303.40
- Ozempic (Drug) $274.91
- TRELEGY ELLIPTA (Drug) $249.07
- ENTRESTO (Drug) $207.21
- FARXIGA (Drug) $185.39
- Descovy (Drug) $181.84
- TRINTELLIX (Drug) $179.12
- XARELTO (Drug) $175.00
- ANORO (Drug) $173.98
- SYMBICORT (Drug) $171.17
- Tresiba (Drug) $170.32
- TRULICITY (Drug) $151.98
- BREZTRI (Drug) $145.72
- VYVANSE (Drug) $123.84
- CHANTIX (Drug) $120.92
- Auvelity (Drug) $118.75
- Trintellix (Drug) $117.73
- AJOVY (Drug) $112.79
- REXULTI (Drug) $91.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Frederick
Dr. Craig Washington, Md, MD
Internal Medicine — Payments: $224,755
Rohan Rengen, D.o, D.O
Internal Medicine — Payments: $38,295
Sibte Kazmi, Md, MD
Internal Medicine — Payments: $14,311
Mouhamad Bazzi, Md, MD
Internal Medicine — Payments: $14,055
Dr. Syed Haque, M.d, M.D
Internal Medicine — Payments: $13,568
Daniel Daniels, M.d, M.D
Internal Medicine — Payments: $11,052